YMRC
TVTX icon

Yorktown Management & Research Company’s Travere Therapeutics TVTX Stock Holding History

Yorktown Management & Research Company’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$415K Buy
+7,300
New +$324K 0.25% 150

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Yorktown Management & Research Company's TVTX Position: Q2 2026 in Review

Yorktown Management & Research Company opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 7,300 shares worth $415K. The stake represents 0.25% of the portfolio and ranks #150 among its holdings.

120 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Yorktown Management & Research Company held 7,300 shares of Travere Therapeutics worth $415K as of Q2 2026.
  • Travere Therapeutics was a new Yorktown Management & Research Company position in Q2 2026.
  • Travere Therapeutics made up 0.25% of Yorktown Management & Research Company's portfolio in Q2 2026, its #150 holding.
  • 120 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.